RORing CAR T cells in solid and hematological cancers: same but different
0
Authors
Sebastian Kobold
Sebastian Kobold
Published
December 3, 2024
Abstract
Abstract A recent phase I clinical study tested anti-ROR1 CAR T cells in patients with CLL, NSCLC, and TNBC. The product could be safely administered and had activity in CLL but less so in NSCLC and TNBC.
